Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its ...
AbbVie (ABBV) took a big hit after an adult schizophrenia drug missed its primary endpoint in mid-stage trials. Analysts are ...
Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...
5h
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY – Research Report) ...
2 Beaten-Down Dividend Stocks to Buy and Hold was originally published by The Motley Fool Despite soft inflation print, bond ...
Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.
Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback